Literature DB >> 20713460

Protein expression analysis of chronic lymphocytic leukemia defines the effect of genetic aberrations and uncovers a correlation of CDK4, P27 and P53 with hierarchical risk.

Dirk Winkler1, Christof Schneider, Manuela Zucknick, Daniela Bögelein, Kerstin Schulze, Thorsten Zenz, Julia Mohr, Angela Philippen, Henriette Huber, Andreas Bühler, Annett Habermann, Axel Benner, Hartmut Döhner, Stephan Stilgenbauer, Daniel Mertens.   

Abstract

BACKGROUND: Chronic lymphocytic leukemia has a variable clinical course. Genomic aberrations identify prognostic subgroups, pointing towards distinct underlying biological mechanisms that are poorly understood. In particular it remains unclear whether the prognostic subgroups of chronic lymphocytic leukemia are characterized by different levels of leukemogenic proteins. DESIGN AND METHODS: Expression of 23 proteins involved in apoptosis, proliferation, DNA damage, and signaling or whose genes map to chromosomal regions known to be critical in chronic lymphocytic leukemia was quantified in 185 cytogenetically well characterized cases of chronic lymphocytic leukemia using immunoblotting. Cases were categorized hierarchically into deletion(17p), deletion(11q), trisomy 12, deletion(13q) as sole abnormality or normal karyotype. Statistical analysis was performed for expression differences between these subgroups. In addition, the expression levels of CDK4, P27 and P53 were quantified over the clinical course and compared to levels in immunopurified B cells from healthy individuals.
RESULTS: In subgroups with a good prognosis, differential expression was mainly seen for proteins that regulate apoptosis. In contrast, in cytogenetic subgroups with a worse prognosis, differential expression was mostly detected for proteins that control DNA damage and proliferation. Expression levels of CDK4, P27 and P53 were higher compared to those in B cells from healthy individuals and significantly correlated with increasing hierarchical risk. In addition, no significant longitudinal changes of expression levels of CDK4, P27 and P53 could be detected in chronic lymphocytic leukemia patients.
CONCLUSIONS: Differences in expression levels of apoptosis- and proliferation-controlling proteins define distinct prognostic subgroups of chronic lymphocytic leukemia and uncover a correlation of levels of CDK4, P27 and P53 proteins with higher hierarchical risk.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20713460      PMCID: PMC2966910          DOI: 10.3324/haematol.2010.025734

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  47 in total

1.  AKT inhibitor, GSK690693, induces growth inhibition and apoptosis in acute lymphoblastic leukemia cell lines.

Authors:  Dana S Levy; Jason A Kahana; Rakesh Kumar
Journal:  Blood       Date:  2008-12-08       Impact factor: 22.113

2.  17p13/TP53 deletion in B-CLL patients is associated with microRNA-34a downregulation.

Authors:  M K Dijkstra; K van Lom; D Tielemans; F Elstrodt; A W Langerak; M B van 't Veer; M Jongen-Lavrencic
Journal:  Leukemia       Date:  2008-09-25       Impact factor: 11.528

3.  Rapid ATM-dependent phosphorylation of MDM2 precedes p53 accumulation in response to DNA damage.

Authors:  R Khosravi; R Maya; T Gottlieb; M Oren; Y Shiloh; D Shkedy
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-21       Impact factor: 11.205

Review 4.  From pathogenesis to treatment of chronic lymphocytic leukaemia.

Authors:  Thorsten Zenz; Daniel Mertens; Ralf Küppers; Hartmut Döhner; Stephan Stilgenbauer
Journal:  Nat Rev Cancer       Date:  2009-12-03       Impact factor: 60.716

Review 5.  Cyclin-dependent kinase inhibitors as potential targeted anticancer agents.

Authors:  Ivan Diaz-Padilla; Lillian L Siu; Ignacio Duran
Journal:  Invest New Drugs       Date:  2009-03-05       Impact factor: 3.850

6.  MicroRNAs in chronic lymphocytic leukemia pathogenesis and disease subtypes.

Authors:  Marek Mraz; Sarka Pospisilova; Karla Malinova; Ivo Slapak; Jiri Mayer
Journal:  Leuk Lymphoma       Date:  2009-03

7.  Chronic lymphocytic leukemia and 13q14: miRs and more.

Authors:  Daniel Mertens; Angela Philippen; Melanie Ruppel; Danilo Allegra; Nupur Bhattacharya; Cordula Tschuch; Stephan Wolf; Irina Idler; Thorsten Zenz; Stephan Stilgenbauer
Journal:  Leuk Lymphoma       Date:  2009-03

8.  miR-34a as part of the resistance network in chronic lymphocytic leukemia.

Authors:  Thorsten Zenz; Julia Mohr; Eric Eldering; Arnon P Kater; Andreas Bühler; Dirk Kienle; Dirk Winkler; Jan Dürig; Marinus H J van Oers; Daniel Mertens; Hartmut Döhner; Stephan Stilgenbauer
Journal:  Blood       Date:  2008-10-21       Impact factor: 22.113

9.  miR-15a and miR-16 are implicated in cell cycle regulation in a Rb-dependent manner and are frequently deleted or down-regulated in non-small cell lung cancer.

Authors:  Nora Bandi; Samuel Zbinden; Mathias Gugger; Marlene Arnold; Verena Kocher; Lara Hasan; Andreas Kappeler; Thomas Brunner; Erik Vassella
Journal:  Cancer Res       Date:  2009-06-23       Impact factor: 12.701

10.  Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab.

Authors:  Farrukh T Awan; Neil E Kay; Melanie E Davis; Wenting Wu; Susan M Geyer; Nelson Leung; Diane F Jelinek; Renee C Tschumper; Charla R Secreto; Thomas S Lin; Michael R Grever; Tait D Shanafelt; Clive S Zent; Timothy G Call; Nyla A Heerema; Gerard Lozanski; John C Byrd; David M Lucas
Journal:  Blood       Date:  2008-11-13       Impact factor: 22.113

View more
  1 in total

1.  Prognostic models for newly-diagnosed chronic lymphocytic leukaemia in adults: a systematic review and meta-analysis.

Authors:  Nina Kreuzberger; Johanna Aag Damen; Marialena Trivella; Lise J Estcourt; Angela Aldin; Lisa Umlauff; Maria Dla Vazquez-Montes; Robert Wolff; Karel Gm Moons; Ina Monsef; Farid Foroutan; Karl-Anton Kreuzer; Nicole Skoetz
Journal:  Cochrane Database Syst Rev       Date:  2020-07-31
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.